The longterm effects of ketamine on haemodynamic parameters and exogenous catecholamine requirements were studied in twenty-five critically ill patients with catecholamine-dependent heart failure. Following sedation with midazolam (0.15±0.07 mg.kg -1 .h -1 ) and sufentanil (0.88±0.33 µg.kg -1 .h -1 ), patients with impaired left ventricular function (left ventricular ejection fraction area 30±7%) were randomly assigned to receive ketamine (2.5±0.9 mg.kg -1 .h -1 ) and midazolam (Group A) or remained on sufentanil/midazolam (Group B). Haemodynamic measurements were performed throughout the first 24 hours after randomization. In group A cardiac index decreased by 21% (P=0.01), mean arterial pressure increased by 13% (P=0.01), mean pulmonary artery pressure by 14% (P=0.04), pulmonary capillary wedge pressure by 20% (P=0.03), and systemic vascular resistance index by 38% (P<0.001). No significant cardiovascular effects were observed in Group B. Neither group had significant changes of exogenous catecholamine requirement.
Anaesthetic agents exert direct and indirect effects on the cardiovascular system. Ketamine, a rapidacting analgesic and dissociative anaesthetic agent, is known for its central stimulatory sympathetic effect, causing hypertension and tachycardia. Some of these side-effects are attenuated by co-administration of benzodiazepines or other hypnotics [1] [2] [3] . Recent studies have suggested that the cardiovascular stimulatory effect of ketamine might be useful in patients with haemodynamic instability 4, 5 . In patients requiring catecholamine therapy, ketamine infusion resulted in reduction of exogenous catecholamine dosage, without adversely affecting the haemodynamic status. This study prospectively compares the cardiovascular effects and catecholamine requirements of ketamine versus sufentanil infusions in critically ill patients with catecholamine-dependent heart failure.
METHODS
Twenty-five mechanically ventilated patients with catecholamine-dependent heart failure (i.e. left ventricular ejection fraction area of less than 40%, and requirement of catecholamines to achieve a cardiac index greater than 2.0 l.min -1 .m -2 and a mean arterial pressure of more than 60 mmHg) were enrolled in this prospective, randomized study. Randomization was performed by opening a sequentially numbered sealed opaque envelope containing treatment allocation determined by a random number table. All patients were haemodynamically stable during baseline studies on sufentanil/midazolam sedation for more than 24 hours. Thereafter, 13 patients were randomized to receive ketamine/midazolam (Group A), while the other 12 patients remained on sufentanil/midazolam (Group B). In both groups a comparable level of sedation, equivalent to Ramsay score 5 (sluggish response to light glabellar tap and loud auditory stimulus) 6 was achieved. Demographic data for both patient groups are summarized in Table 1 .
Haemodynamic measurements were performed prior to switch of sedation (0 hour), and at 1 hour, 4 hours, 8 hours, 16 hours and 24 hours, using a pulmonary artery thermodilution catheter (Edwards Model 93A-831H 7.5F; Baxter Healthcare Corp., Irvine CA). Cardiac output measurements were performed in triplicate by hand injection of 10 ml saline at room temperature.
All randomized patients were haemodynamically stable and treated with catecholamines for more than 24 hours. Patients with haemodynamic instability (mean arterial blood pressure <60 mmHg or variations of mean blood pressure of >20%) or patients with any change in catecholamine requirement within the previous 24 hours were excluded. During the treatment period catecholamine dosage was adjusted to achieve a mean arterial blood pressure above 60 mmHg (but not higher than 80 mmHg). Changes in blood pressure were treated by adjustment of the vasopressor dose, without addition of different catecholamines.
Transoesophageal echocardiography was per-formed at baseline (prior to switch of sedation) with a Vingmed 800 echocardiographic system using a 5 MHz multiplane probe (Vingmed Sound, Inc.). For measurement of left ventricular areas a transgastric midventricular cross-sectional short axis view was obtained. Left ventricular end-diastolic and endsystolic areas were measured off-line from video tape recordings and left ventricular ejection fraction area was calculated as (left ventricular end-diastolic arealeft ventricular endsystolic area)x100/ left ventricular end-diastolic area.
Data analysis
All data are presented as mean ± standard deviation (except for the figure, where standard error of the mean is used). Patient demographic data and baseline values between treatment groups were compared using an unpaired t-test. Haemodynamic data and catecholamine requirements at various timepoints after randomization were compared by analysis of variance for repeated measurements followed by Fisher's exact test. A P value of <0.05 was considered to indicate significant difference.
RESULTS
Baseline haemodynamic data prior to randomization to ketamine (Group A) or sufentanil (Group B) are presented in Table 2 . Apart from a lower central venous pressure in patients randomized to ketamine (Group A), no statistically significant haemodynamic differences between the treatment groups occurred. During mechanical ventilation a slightly lower level of positive end-expiratory pressure was used in group A (5.1±0.8 mmHg vs 6.1±1.4; P=ns). There was no significant difference in the number of patients with atrial fibrillation in both groups (2 in group A vs 3 in group B). All other vasoactive drugs besides those listed in Table 3 (including angiotensin-converting enzyme inhibitors) were withdrawn more than 48 hours before study entry. The mean dosage of midazolam was 0.12±0.04 mg.kg -1 .h -1 in group A, 0.15±0.07 mg.kg -1 .h -1 in group B (P=ns) and remained constant during the study period. The mean dosage of sufentanil was 0.88±0.33 µg.kg -1 .h -1 before randomization and remained unchanged in group B. In group A a comparable level of sedation (Ramsay score 5) was achieved with a ketamine dose of 2.5±0.9 mg.kg -1 .h -1 .
Cardiovascular Effects of Ketamine versus Sufentanil
The effects of ketamine and sufentanil on various haemodynamic parameters are shown in Figure 1 dyn.s.cm -5 .m -2 after 24 hours) without reaching statistical significance. Most haemodynamic changes within the ketamine group developed gradually after initiation of treatment and reached statistical significance after eight hours. Only the increase in mean pulmonary artery pressure was already significant after four hours. In patients randomized to sufentanil no significant cardiovascular effects were observed (Figure 1) .
Catecholamine requirement
Catecholamine requirements at baseline and after randomization to ketamine or sufentanil are listed in Table 3 . At baseline, dopamine, dobutamine and noradrenaline dosage was comparable between the two patient groups. Despite adequate randomization, baseline noradrenaline dosage was higher in patients randomized to sufentanil. During the study period no significant change in catecholamine requirement within the treatment groups occurred. (Table 3 ).
DISCUSSION
The present data demonstrate that longterm sedation with ketamine is associated with adverse cardiovascular effects in patients with catecholaminedependent heart failure. In patients treated with ketamine, arterial blood pressure, systemic vascular resistance, pulmonary capillary wedge pressure and pulmonary arterial pressure increased by 14 to 38%, whereas cardiac index decreased by 21%. In contrast, sufentanil caused no significant haemodynamic alterations.
The haemodynamic changes observed in the ketamine group might be due to direct as well as indirect cardiovascular effects of the drug. A direct myocardial depressant activity of ketamine has been shown after adrenergic and vagal blockade in dogs 1, 7 . In patients with normal left ventricular function, this negative inotropic effect might be counterbalanced by the central stimulatory sympathetic effect of ketamine. Moreover, moderate augmentation of peripheral vascular tone will not adversely affect left ventricular function in patients without cardiac disease. However, in patients with reduced left ventricular function, the increase in afterload induced by ketamine was associated with a decrease in cardiac output and with a concomitant increase of left ventricular diastolic filling pressure. By increasing myocardial oxygen consumption and decreasing oxygen delivery, increases in afterload and preload could have negative consequences on the myocardial oxygen balance. This may be clinically important in patients with unstable angina, with acute myocardial infarction or in the postoperative patient after coronary artery bypass grafting.
Whether the fall in cardiac output was due to a direct myocardial depressant activity of ketamine or secondary to increased systemic vascular resistance must remain unresolved, since no load-independent indices of myocardial contractility were measured. However, the significant increase in systemic vascular resistance during ketamine infusion would suggest that the increase in afterload might have been the predominant mechanism.
Similar unfavourable haemodynamic effects of ketamine have been reported in previous studies during induction of anaesthesia in patients with cardiomyopathy undergoing heart transplantation 8,9 . However, in these studies any adverse longterm haemodynamic effects of ketamine were without consequence, since the diseased heart was removed soon after drug application.
In contrast, two previous studies reported a potentially beneficial effect of ketamine used for sedation in patients with haemodynamic instability 4, 5 . Ketamine at a mean dosage of 50 mg/h decreased exogenous catecholamine requirement in patients with sepsis syndrome. The beneficial effect may have been related to a desirable ketamine-induced increase in systemic vascular resistance. Potential negative inotropic effects of the drug should not be of major clinical relevance in the non-cardiac patient. Nevertheless, both studies revealed also a significant adverse effect related to an undesirable ketamineinduced increase in pulmonary artery pressure. This potential negative effect of ketamine infusion has also been demonstrated in other studies with cardiac patients [8] [9] [10] . As pulmonary vascular resistance is often already elevated in septic patients and patients with pulmonary or cardiac disease, further increases of right ventricular afterload by ketamine might be of clinical relevance.
In contrast to these previous studies, patients in our study required higher doses of ketamine to achieve an equivalent level of sedation to sufentanil. Therefore it remains speculative whether lower doses of ketamine might have exerted less unfavourable haemodynamic effects.
In conclusion, ketamine infusion in patients with catecholamine-dependent heart failure may cause a clinically important impairment of overall cardiac function, without significantly influencing exogenous catecholamine requirement. In contrast, sufentanil did not exhibit negative haemodynamic effects. Thus opioids instead of ketamine should be considered as first-line drugs for longterm sedation of critically ill cardiac patients.
